Life Sciences & Biotechnology
Title : | Alpha V Beta 3 Integrin Aspired Vesicular Nanohybrids Based Neoadjuvant Therapy for Locally Advanced Colon Cancer |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Aakanchha Jain, National Institute Of Pharmaceutical Education And Research (NIPER) Ahmedabad, Gujarat |
Timeline Start Year : | 2023 |
Timeline End Year : | 2025 |
Contact info : | aakanchha.jain@niperahm.ac.in |
Details
Executive Summary : | Neoadjuvant therapy is a treatment used to reduce tumor size or make it easier to remove, used for various types of cancer. Nanomedicine, using nanotechnology, can diagnose, treat, and prevent diseases. In the context of multidrug resistant colon cancer, nanomedicine offers a promising solution by allowing targeted delivery of therapeutic agents directly to the tumor site. The results could impact the field by improving cancer treatment with lesser morbidity, mortality, and metastasis, and potentially reducing the need for surgery. Methodology involved evaluating particle size, surface charge, loading efficiency, particle density, in-vitro drug release, and stability of established vesicular nanohybrids. |
Total Budget (INR): | 31,34,764 |
Organizations involved